Search for: "WATSON PHARMACEUTICALS, INC."
Results 61 - 80
of 224
Sort by Relevance
|
Sort by Date
1 Apr 2013, 8:29 am
” Upon receiving this reissue patent, Pfizer immediately filed a lawsuit against Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Watson Laboratories, Inc.; Lupin Pharmaceuticals, USA, Inc.; Apotex Corp.; and Apotex, Inc. in the United States District Court for the Eastern District of Virginia for infringement of the reissue patent. [read post]
13 Mar 2013, 1:55 pm
Watson Pharmaceuticals, Inc., a case concerning reverse payment settlements of patent litigation. [read post]
13 Mar 2013, 4:45 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
12 Mar 2013, 6:40 am
Watson Pharmaceuticals, Inc., a case concerning reverse payment settlements of patent litigation. [read post]
10 Mar 2013, 9:59 pm
Searle LLC; Pfizer Asia Pacific PTE, LTD.; • Defendants: Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Watson Laboratories, Inc.; Apotex Inc.; Apotex Corp. [read post]
25 Feb 2013, 11:00 pm
Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court’s finding that two Orange Book-listed patents for Cephalon’s FENTORA® product were invalid, but affirmed the district court’s finding that Watson’s ANDA product would not... [read post]
14 Feb 2013, 9:59 pm
By Kevin E. [read post]
6 Feb 2013, 4:43 pm
Watson Pharmaceuticals Inc. and Impax Laboratories Inc. both sent letters to Purdue in December, informing the company of their plans to make a generic form of the drug. [read post]
1 Feb 2013, 10:32 am
Watson Pharmaceuticals. [read post]
15 Jan 2013, 11:33 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
13 Jan 2013, 9:06 pm
• Defendants: Apotex Inc.; Apotex Corp.; Sandoz, Inc.; Hi-Tech Pharmacal Co., Inc.; Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Watson Pharma, Inc. [read post]
9 Jan 2013, 11:01 pm
Watson Pharmaceuticals, Inc., to address whether and when “reverse payment” agreements made to settle ANDA litigation violate antitrust laws. [read post]
15 Nov 2012, 7:50 am
Watson of the U.S. [read post]
12 Nov 2012, 4:14 pm
In Matrixx Initiatives, Inc. v. [read post]
31 Oct 2012, 10:31 am
He also represented Watson Pharmaceuticals Inc. in its $5.9 billion purchase of Swiss drug maker Actavis Inc., which was approved by the FTC (with divestitures) earlier in October. [read post]
23 Oct 2012, 6:30 am
Watson Pharmaceuticals, Inc., No. 12-416 (U.S. [read post]
19 Oct 2012, 6:13 pm
For two other drugs, Watson and Actavis would be required to relinquish the marketing rights to another firm.The case is Watson Pharmaceuticals, Inc., FTC Dkt. [read post]
5 Oct 2012, 11:43 am
Watson Pharmaceuticals, Inc. [read post]
28 Sep 2012, 11:15 am
Watson Pharmaceuticals, Inc., No. 10-12729, where the Eleventh Circuit upheld reverse payments -- finding no antitrust violation in settlements involving generic Androgel. [read post]
16 Sep 2012, 5:12 pm
Watson Pharmaceuticals, Inc., 677 F.3d 1298 (11th Cir. 2012). [read post]